1. Locally Advanced Lung Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction Staging

5. Discussion on Surgically Resectable vs Unresectable Tumors

6. Factors to Consider When Choosing Between Concurrent or Sequential CRT

7. Concurrent CRT Increases OS Benefit

8. Deciding Which Chemotherapy to Use

9. Introduction Checkpoint Inhibitors

10. Rationale for Immunotherapy After CRT

11. PACIFIC Trial Study Design

12. PACIFIC Trial PFS in the ITT Population

13. PACIFIC Trial Subgroup Analysis of Prognostic Factors for PFS

14. Best Practices for Scanning After CRT

15. PACIFIC Trial Rationale for Performing Scan Immediately After CRT

16. PACIFIC Trial Metastases in the ITT Population

17. Limitations of the PACIFIC Trial

18. Assessments That Should Be Performed Before CRT

19. Key Takeaways From PACIFIC Trial

20. imAEs

21. Monitoring for imAEs

22. PACIFIC Trial Safety Profile

23. Managing Pneumonitis in Patients Receiving Durvalumab After CRT

24. Treatment Approach to Surgically Resectable vs Surgically Unresectable Patient Population

25. Phase 2 Study of Pembrolizumab After LAT in Patients With Oligometastatic NSCLC

26. Conclusions and Ongoing Studies

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)